Amarin gets a boost from the FDA as regulators promise speedy Vascepa decision — but what about that panel review?

There’s plenty of buzz today about Amarin $AMRN and its quest to get cardio outcomes data added to the label for Vascepa, its therapeutic strength version of fish oil.

The FDA has given their sNDA priority review status, leaving a decision on opening up the market for this therapy just 4 short months away on September 28. The move lops months off the regulatory process and moves a potential approval into Q3 of this year — one of the biggest catalysts on the H2 calendar.